The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Boston Scientific Corporation. (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”). Boston Scientific investors have until May 4, 2026 to file a lead plaintiff motion.

What Happened?

On February 4, 2026, Boston Scientific reported fourth quarter and full year 2025 results, including a disappointment in U.S. Electrophysiology sales, and issued fiscal 2026 guidance – including for the first half of 2026 – that fell below expectations. The Company attributed the results to slower than expected market growth and increased competition, despite prior statements describing the EP business as “growing” and asserting it had “a very good understanding of what competition we will face and in what time frame.”

On this news, Boston Scientific’s stock price fell $16.12, or 17.6%, to close at $75.50 per share on February 4, 2026, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Boston Scientific’s U.S. EP segment’s growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing new competition entrants that were sapping Boston Scientific’s U.S. Electrophysiology market share and thus limiting the Company’s growth potential; (3) as a result, Defendants’ repeated statements of confidence in the U.S. EP division’s growth trajectory, including repeatedly elevated full-year guidance metrics, were materially misleading; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.